DK0610254T3 - Glial-afledt neurotrofisk faktor - Google Patents

Glial-afledt neurotrofisk faktor

Info

Publication number
DK0610254T3
DK0610254T3 DK92921022T DK92921022T DK0610254T3 DK 0610254 T3 DK0610254 T3 DK 0610254T3 DK 92921022 T DK92921022 T DK 92921022T DK 92921022 T DK92921022 T DK 92921022T DK 0610254 T3 DK0610254 T3 DK 0610254T3
Authority
DK
Denmark
Prior art keywords
gdnf
neurotrophic factor
derived neurotrophic
glial
vector
Prior art date
Application number
DK92921022T
Other languages
Danish (da)
English (en)
Inventor
Daniel H Doherty
Leu-Fen H Lin
Franklin D Collins
Jack Lile
Susan Bektesh
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK0610254T3 publication Critical patent/DK0610254T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK92921022T 1991-09-20 1992-09-17 Glial-afledt neurotrofisk faktor DK0610254T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US76468591A 1991-09-20 1991-09-20
US77410991A 1991-10-08 1991-10-08
US78842391A 1991-11-06 1991-11-06
US85541392A 1992-03-19 1992-03-19
PCT/US1992/007888 WO1993006116A1 (en) 1991-09-20 1992-09-17 Glial derived neurotrophic factor

Publications (1)

Publication Number Publication Date
DK0610254T3 true DK0610254T3 (da) 2005-01-10

Family

ID=27505700

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92921022T DK0610254T3 (da) 1991-09-20 1992-09-17 Glial-afledt neurotrofisk faktor

Country Status (21)

Country Link
US (7) US7226758B1 (no)
EP (2) EP1243652A3 (no)
KR (1) KR100242093B1 (no)
AT (1) ATE275197T1 (no)
AU (2) AU679167B2 (no)
CA (1) CA2119463C (no)
DE (1) DE69233407T2 (no)
DK (1) DK0610254T3 (no)
ES (1) ES2225819T3 (no)
FI (1) FI117556B (no)
GE (1) GEP20002243B (no)
HK (2) HK1017816A1 (no)
HU (2) HU220795B1 (no)
IL (5) IL103223A (no)
MX (1) MX9205293A (no)
NO (1) NO321382B1 (no)
NZ (1) NZ244392A (no)
PT (1) PT100879B (no)
SG (1) SG48145A1 (no)
TW (1) TW401422B (no)
WO (1) WO1993006116A1 (no)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
CA2170751A1 (en) * 1993-09-01 1995-03-09 Timothy J. Cunningham Neuron regulatory factor for promoting neuron survival
WO1995017203A1 (en) * 1993-12-22 1995-06-29 The University Of Medicine And Dentistry Of New Jersey Novel nucleic acid sequences isolated from glial cells
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6472585B1 (en) 1994-04-25 2002-10-29 Genentech, Inc. Cardiotrophin-1 defective mouse
US7258983B2 (en) 1994-04-25 2007-08-21 Genentech, Inc. Cardiotrophin-1 compositions and methods for the treatment of tumor
ES2276393T3 (es) * 1994-04-25 2007-06-16 Genentech, Inc. Cardiotrofina y sus usos.
US5853385A (en) * 1994-08-26 1998-12-29 Cytotherapeutics, Inc. Encapsulated PC12 cell transplants for treatment of Parkinson's disease
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
JP3093974B2 (ja) * 1995-06-27 2000-10-03 住友ベークライト株式会社 神経細胞用培養液、その製造方法及びこれを用いる神経細胞の培養方法
US6743628B1 (en) 1995-08-28 2004-06-01 Washington University Method of cell culture using neurturin
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
WO1997019693A1 (en) * 1995-11-29 1997-06-05 Amgen Inc. Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
AU716846B2 (en) * 1996-03-14 2000-03-09 Washington University Persephin and related growth factors
US6716600B1 (en) 1996-03-14 2004-04-06 Washington University Persephin and related growth factors
ATE247667T1 (de) * 1996-03-14 2003-09-15 Genentech Inc Gdnf-rezeptor und dessen verwendung
US6222022B1 (en) 1996-03-14 2001-04-24 Washington University Persephin and related growth factors
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6455277B1 (en) 1996-04-22 2002-09-24 Amgen Inc. Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
US7138251B1 (en) 1996-04-22 2006-11-21 Amgen Inc. Polynucleotides encoding a neurotrophic factor receptor
WO1997039629A1 (en) * 1996-04-25 1997-10-30 Genetic Therapy, Inc. Viral vectors including polynucleotides encoding neurotrophic factors and uses therefor
ES2213221T3 (es) * 1996-07-29 2004-08-16 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh Factor de tipo egf de granulos de cromafina y factor neurotrofico derivado de celulas de glia con actividad promotora de la supervivencia sobre neuronas daergicas.
AU6020998A (en) 1997-01-08 1998-08-03 Life Technologies, Inc. Methods for production of proteins
US6777196B2 (en) 1997-02-18 2004-08-17 Genentech, Inc. Neurturin receptor
US6372453B1 (en) 1997-02-18 2002-04-16 Genetech, Inc. Neurturin receptor
US6025157A (en) * 1997-02-18 2000-02-15 Genentech, Inc. Neurturin receptor
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
EP1304119A3 (en) * 1997-07-30 2004-01-21 Amgen Inc. Method for preventing and treating hearing loss using a neurturin protein product
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
CA2299586C (en) * 1997-08-05 2007-09-18 F. Hoffmann-La Roche Ag Human glial cell line-derived neurotrophic factor promoters, vectors containing same, and methods of screening compounds therewith
WO1999049039A2 (en) 1998-03-23 1999-09-30 Genentech, Inc. GFRα3 AND ITS USES
US7026138B1 (en) 1998-03-23 2006-04-11 Genentech, Inc. Polynucleotides encoding GFRα3
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
US7060676B2 (en) * 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
US6426065B1 (en) * 2000-11-07 2002-07-30 Clairol Incorporated Use of tris(hydroxymethyl)aminomethane in cold permanent waving processes
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
EP1395279B1 (en) 2001-03-28 2011-10-05 Biogen Idec MA Inc. Use of neublastin polypeptides for treating neuropathic pain
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
US7613491B2 (en) * 2002-05-22 2009-11-03 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US8364229B2 (en) * 2003-07-25 2013-01-29 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US7497827B2 (en) 2004-07-13 2009-03-03 Dexcom, Inc. Transcutaneous analyte sensor
US7828728B2 (en) * 2003-07-25 2010-11-09 Dexcom, Inc. Analyte sensor
WO2003090689A2 (en) * 2002-04-25 2003-11-06 Wisconsin Alumni Research Foundation Neurodegenerative disorder treatment using gdnf secreting neural cells
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
US7528112B2 (en) 2002-11-15 2009-05-05 Drexel University Small survival-promoting/immunomodulatory peptide for treatment of brain damage, neurodegenerative disorders, and inflammatory disorders
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
JP2006517101A (ja) * 2003-01-13 2006-07-20 エス． ラオ、マヘンドラ 治療用産物を送達するための、増殖性の幹細胞および前駆細胞における候補分子の持続的発現
US20040209810A1 (en) * 2003-02-24 2004-10-21 Gill Steven S. Method of treating Parkinson's disease in humans by intraputaminal infusion of glial cell-line derived neurotrophic factor
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
ES2479942T3 (es) 2003-04-18 2014-07-25 Biogen Idec Ma Inc. Neublastina glucosilada conjugada con polímero
US7875293B2 (en) * 2003-05-21 2011-01-25 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
ATE423134T1 (de) 2003-06-10 2009-03-15 Nsgene As Verbesserte sezernierung von neublastin
US9763609B2 (en) 2003-07-25 2017-09-19 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
EP1648298A4 (en) * 2003-07-25 2010-01-13 Dexcom Inc OXYGEN-IMPROVED MEMBRANE SYSTEMS FOR IMPLANTABLE DEVICES
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US9135402B2 (en) 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
EP1662879A4 (en) * 2003-08-29 2009-03-11 Univ New York INDIRECT ADMINISTRATION OF GROWTH FACTORS IN THE CENTRAL NERVOUS SYSTEM
WO2005023861A2 (en) * 2003-09-05 2005-03-17 Licentia, Ltd. Gdnf-related neuropeptides
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
US20060239966A1 (en) * 2003-10-20 2006-10-26 Tornoee Jens In vivo gene therapy of parkinson's disease
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US20050123526A1 (en) * 2003-12-01 2005-06-09 Medtronic Inc. Administration of growth factors for neurogenesis and gliagenesis
US8093205B2 (en) * 2003-12-01 2012-01-10 Medtronic, Inc. Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis
US7364592B2 (en) * 2004-02-12 2008-04-29 Dexcom, Inc. Biointerface membrane with macro-and micro-architecture
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
GB2414934A (en) * 2004-06-11 2005-12-14 Gill Steven Streatfield Treatment of Parkinson's disease with GDNF
CA2568150A1 (en) * 2004-06-21 2006-01-05 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
AU2005277227B2 (en) 2004-08-19 2011-10-06 Biogen Ma Inc. Refolding transforming growth factor beta family proteins
RS51453B (en) 2004-08-19 2011-04-30 Biogen Idec Ma Inc. NEUBLASTIN
US8133178B2 (en) 2006-02-22 2012-03-13 Dexcom, Inc. Analyte sensor
WO2007019860A2 (en) * 2005-08-16 2007-02-22 Copenhagen University Gdnf derived peptides
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
JP2009513584A (ja) * 2005-10-28 2009-04-02 エヌエスゲーネ・アクティーゼルスカブ Ｇｄｎｆの送達のための移植可能な生体適合性免疫隔離ビヒクル
DE602005023550D1 (de) 2005-12-14 2010-10-21 Licentia Ltd Verwendungen eines neurotrophischen Faktors
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
ES2618787T5 (es) 2006-04-25 2022-10-21 Univ California Administración de factores de crecimiento para el tratamiento de trastornos del SNC
US20070259031A1 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
EP1872790A1 (en) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin
WO2008022349A2 (en) * 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
KR100770440B1 (ko) * 2006-08-29 2007-10-26 삼성전기주식회사 질화물 반도체 발광소자
US8637459B2 (en) * 2006-11-08 2014-01-28 Emory University Enhancing a population of insulin releasing cells using GFR-A1 agonists
JP5583005B2 (ja) 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
US20200037874A1 (en) 2007-05-18 2020-02-06 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
EP2167071B1 (en) * 2007-06-13 2020-03-18 Wayne State University Board Of Governors A baclofen solution for low-volume therapeutic delivery
WO2008157308A2 (en) * 2007-06-13 2008-12-24 Wayne State University Board Of Governors A zwitterion solution for low-volume therapeutic delivery
CA3184105A1 (en) * 2007-07-27 2009-02-05 Armagen Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
EP2227132B1 (en) 2007-10-09 2023-03-08 DexCom, Inc. Integrated insulin delivery system with continuous glucose sensor
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
US8290559B2 (en) * 2007-12-17 2012-10-16 Dexcom, Inc. Systems and methods for processing sensor data
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
US20090247856A1 (en) 2008-03-28 2009-10-01 Dexcom, Inc. Polymer membranes for continuous analyte sensors
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
BRPI0912683A2 (pt) 2008-05-15 2016-01-26 Transmolecular Inc tratamento de tumores metastáticos
EP2396408B1 (en) 2009-02-12 2017-09-20 CuRNA, Inc. Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
JP5873003B2 (ja) 2009-03-18 2016-03-01 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
DK2485761T3 (da) 2009-10-09 2019-05-06 Armagen Inc Fremgangsmåder og sammensætninger til øgning af iduronat-2-sulfatase-aktivitet i CNS
WO2011064437A2 (es) 2009-11-26 2011-06-03 Proyecto De Biomedicina Cima, S.L. Vectores virales y procedimientos útiles en la preparación de gdnf
CN102844044B (zh) 2010-02-04 2016-10-26 摩尔弗泰克有限公司 氯毒素多肽和结合物及其应用
EP2569330B1 (en) 2010-05-11 2016-09-28 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
WO2012075184A2 (en) 2010-12-02 2012-06-07 Neurotech Usa, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
UA112981C2 (uk) 2011-04-11 2016-11-25 Елі Ліллі Енд Компані Варіант людського gdnf
US20130053666A1 (en) 2011-08-26 2013-02-28 Dexcom, Inc. Polymer membranes for continuous analyte sensors
EP2785378B1 (en) 2011-12-02 2020-05-13 Armagen, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
US9788765B2 (en) 2012-09-28 2017-10-17 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
AU2013359429A1 (en) 2012-12-10 2015-07-09 Fred Hutchinson Cancer Research Center Methods for screening
US10376562B2 (en) 2013-03-15 2019-08-13 The Jackson Laboratory Methods for promoting wound healing and hair growth comprising GDNF administration
US9737250B2 (en) 2013-03-15 2017-08-22 Dexcom, Inc. Membrane for continuous analyte sensors
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US10369329B2 (en) 2014-01-30 2019-08-06 Renishaw Plc Neurosurgical apparatus and method
CN106460062A (zh) 2014-05-05 2017-02-22 美敦力公司 用于scd、crt、crt‑d或sca治疗识别和/或选择的方法和组合物
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
GB201506052D0 (en) 2015-04-09 2015-05-27 Renishaw Plc Movement disorder
US10456356B2 (en) 2015-05-27 2019-10-29 Neurotech Usa, Inc. Use of encapsulated cell therapy for treatment of ophthalmic disorders
JP6983765B2 (ja) 2015-12-30 2021-12-17 デックスコム・インコーポレーテッド 分析物センサのための酵素固定化接着層
CA3021011A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
AU2017357931A1 (en) 2016-11-10 2019-06-20 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
AU2022238919A1 (en) 2021-03-19 2023-10-19 Dexcom, Inc. Drug releasing membrane for analyte sensor
WO2023043908A1 (en) 2021-09-15 2023-03-23 Dexcom, Inc. Bioactive releasing membrane for analyte sensor
TW202325850A (zh) 2021-11-29 2023-07-01 大陸商上海瑞宏迪醫藥有限公司 Aadc、gdnf多核苷酸及其用於治療帕金森病
CA3228457A1 (en) 2022-02-02 2023-08-10 Dexcom, Inc. Sensing systems and methods for diagnosing, staging, treating, and assessing risks of liver disease using monitored analyte data
AU2023224275A1 (en) 2022-02-23 2024-09-12 Dexcom, Inc. Sensing systems and methods for providing decision support around kidney health and/or diabetes
WO2023235443A1 (en) 2022-06-01 2023-12-07 Dexcom, Inc. Sensing systems and methods for diagnosing kidney disease
US20240090802A1 (en) 2022-09-02 2024-03-21 Dexcom, Inc. Continuous analyte sensor devices and methods
US20240225490A1 (en) 2022-12-30 2024-07-11 Dexcom, Inc. Sensing systems and methods for hybrid glucose and ketone monitoring

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518526A (en) * 1982-12-22 1985-05-21 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
DE3587022T2 (de) 1984-02-17 1993-06-17 Genentech Inc Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
US4886747A (en) 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US5284763A (en) 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US5089396A (en) 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US5427780A (en) 1985-10-30 1995-06-27 Biogen, Inc. Composition comprising Mullerian inhibiting substance-like polypeptides
EP0233838A3 (en) * 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
US5187076A (en) * 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5324819A (en) 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
AU652537B2 (en) * 1988-11-04 1994-09-01 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5017735A (en) 1989-07-24 1991-05-21 Catalytica, Inc. Selective sorption of 2,6-diisopropylnaphthalene
AU6174490A (en) * 1989-08-04 1991-03-11 Board Of Regents, The University Of Texas System Methods and compositions; purified preparation of neural progenitor regulatory factor
EP0486584A4 (en) 1989-08-11 1993-02-03 Hahnemann University Dopaminergic neurotrophic factor for treatment of parkinson's disease
US5215969A (en) 1989-08-11 1993-06-01 Hahnemann University Dopaminergic neurotrophic factor for treatment of Parkinson's disease
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5270181A (en) 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules

Also Published As

Publication number Publication date
AU694387B2 (en) 1998-07-16
HK1017816A1 (en) 1999-11-26
HK1047438A1 (zh) 2003-02-21
US7226758B1 (en) 2007-06-05
FI941285A (fi) 1994-03-18
AU679167B2 (en) 1997-06-26
FI941285A0 (fi) 1994-03-18
AU1900197A (en) 1997-09-18
KR940702505A (ko) 1994-08-20
CA2119463A1 (en) 1993-04-01
IL140653A0 (en) 2002-02-10
EP0610254B1 (en) 2004-09-01
US5935795A (en) 1999-08-10
IL140654A0 (en) 2002-02-10
DE69233407T2 (de) 2005-09-08
HUT66137A (en) 1994-09-28
TW401422B (en) 2000-08-11
US20020197675A1 (en) 2002-12-26
GEP20002243B (en) 2000-09-25
HU9400717D0 (en) 1994-06-28
NO321382B1 (no) 2006-05-02
US6221376B1 (en) 2001-04-24
EP1243652A2 (en) 2002-09-25
US6362319B1 (en) 2002-03-26
SG48145A1 (en) 1998-04-17
EP0610254A1 (en) 1994-08-17
NZ244392A (en) 1995-03-28
DE69233407D1 (de) 2004-10-07
IL103223A0 (en) 1993-02-21
NO940922L (no) 1994-05-19
CA2119463C (en) 2003-09-16
WO1993006116A1 (en) 1993-04-01
NO940922D0 (no) 1994-03-15
EP1243652A3 (en) 2003-03-26
EP0610254A4 (en) 1995-05-03
HU211984A9 (en) 1996-01-29
PT100879B (pt) 1999-08-31
ES2225819T3 (es) 2005-03-16
KR100242093B1 (ko) 2000-02-01
FI117556B (fi) 2006-11-30
HU220795B1 (hu) 2002-05-28
IL147488A0 (en) 2002-08-14
MX9205293A (es) 1993-05-01
US6015572A (en) 2000-01-18
AU2681192A (en) 1993-04-27
IL121913A0 (en) 1998-03-10
IL103223A (en) 2005-06-19
US6093802A (en) 2000-07-25
ATE275197T1 (de) 2004-09-15
PT100879A (pt) 1994-02-28

Similar Documents

Publication Publication Date Title
DK0610254T3 (da) Glial-afledt neurotrofisk faktor
DE69229572D1 (de) Gliazellen-aktivierender Faktor und dessen Herstellung
DE68927153D1 (de) Biosynthetische osteogene proteine und sie enthaltende osteogene vorrichtungen
CA2094027A1 (en) Osteogenic peptides
EP0559769A4 (en) Heparin binding mitogen with homology to epidermal growth factor (egf)
BG101408A (en) Analogs of keratinocyte growth factor
AU7869487A (en) Expression of biologically active factor XIII
IE871871L (en) Cloning and expression of acidic fibroblast growth factor
EP0479071A3 (en) Polypeptide
DE69431068D1 (de) Das polypeptid eines membran-proteins mit der funktion zur unterstützung des wachstums von prä-b zellen und sein gen
ATE346919T1 (de) Nebenhoden-spezifisches rezeptorprotein und dessen verwendung
CA2324649A1 (en) Human p51 genes and gene products thereof
Bartzatt et al. Isoelectric focusing of Sendai virus protein by chromatofocusing.
Baird et al. 4956455 Bovine fibroblast growth factor
Clark et al. 4959455 Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
Brown et al. 4959353 Promotion of corneal stroma wound healing with human epidermal growth factor prepared from recombinant DNA
DK171489A (da) Peptidderivater